Skip to main content
PLOS One logoLink to PLOS One
. 2025 Jun 13;20(6):e0323917. doi: 10.1371/journal.pone.0323917

Evaluating turnaround time to improve clients’ satisfaction in the tuberculosis reference laboratory in Douala

Teyim Pride Mbuh 1,2,*, Anya Priscilla Amveilla 1,3, Patricia Mendjime 1,3, Valérie Flore Donkeng Donfack 4, Mohamed Youssouf Mfouapon 1, Hamada Beloko 2, Bisso Ngono Annie Prudence 5, Esso Linda 1,3, Georges Alain Etoundi Mballa 1,3
Editor: Enoch Aninagyei6
PMCID: PMC12165355  PMID: 40512739

Abstract

Introduction

Delivery delays of laboratory results can result in death and/or economic loss to both the patient and the health system. Data is limited regarding turnaround time for tuberculosis testing in Cameroon. We evaluated intra- turnaround time in tuberculosis diagnosis, identified root causes, and brainstormed solutions to improve patient satisfaction.

Materials and methods

In this cross-sectional descriptive study, turnaround time for the pre-analytic phase was set at 3 hours, the analytic phase at 11 hours, and the post-analytic phase at 10 hours. The overall turnaround time was 24 hours. We used the Fishbone method of problem analysis involving the personnel of the Tuberculosis Reference Laboratory-Douala, to identify root causes. We brainstormed using the “Whys” causes of turnaround time failure during the process of tuberculosis diagnosis by GeneXpert MTB/RIF

Results

We analyzed samples from 526 clients. The median turnaround time was 45 (Range: 2-120) hours. A total of 216(41.1%) clients had a turnaround time failure. The turnaround time failures in the pre-analytic, analytic, and post-analytics phases were 64(29.6%), 128(59.3%), and 12(11.1%) respectively. Overall, 19 root causes of turnaround time failure were identified and grouped into six categories, namely: equipment, administration, technical-staff, environment, material, and method. Equipment maintenance (defective or non-calibrated modules) was the critical cause of turnaround time failures accounting for 86 (39.8%) of the overall turnaround time failure.

Conclusion

turnaround time in tuberculosis diagnosis is longer than expected, retarding patient care management. Focusing on equipment maintenance enhances the intra-laboratory testing process, thus improving overall patient satisfaction. The need for further studies to incorporate the extra-laboratory turnaround time in assessing the overall turnaround time is imperative.

Introduction

In 1999, the Institute of Medicine (IOM) in their publication” to Err Is Human” [1], defined medical errors as the inability to carry out specific actions the ought to have been performed as planned or when planned. They qualified most of the medical errors to defective quality management systems which could be avoided by conceiving and monitoring safer healthcare systems and processes that diminish and avert errors, and encourage better outcomes [1]. Though numerous medical errors can be avoided, many healthcare systems, do not implement best practices and provide optimal-quality medical care, this is particular in resource-limited settings. Most medical decisions are made on the basis of laboratory findings. So, clinical laboratory findings must be accurate and timely [2]. The time interval between the specimen reception in the laboratory and the result delivery is known as laboratory waiting time or turnaround time(TAT) [3,4].

The long time patient and clinicians spends waiting for their results is often disappointing. A strong and inverse relationship has been demonstrated between patient satisfaction and result delivery TAT in an ambulatory setting [5]. Early results delivery can lead to prompt treatment which will shortened hospital stay and become an important factor that can help patients to reduction their expenses [6]. Clinical laboratories, most often, focus on the accuracy and reliability of the test results but pay very little attention to how prompt these results are released [7].

TAT is a measure of timeliness and is usually considered as an indicator for laboratory efficiency [8]. TAT is crucial form both a medical and commercial point of view. This has been explained by the reaction of most people to life situations. Most of them are usually impatient requiring that things be done timely including their clinical laboratory results. This may explain why some people prefer health facilities with the reputation of providing proper diagnosis, treatment, and management of their health problems without necessarily compromising the notion of timely services. Late result delivery can be fatal to patients [9]. Delayed TAT may be caused by factors attributed within the laboratory or out of the laboratory. TAT associated to factors within the laboratory itself are usually termed Intra-laboratory TAT while those associated to factors out of the laboratory are termed extra-laboratory TAT

The laboratory pre-analytical TAT phase refers to the time interval between the requisition of a test and the sample reaching the hands of laboratory staff. The analytical phase is that between the beginning of the analysis and the definitive test results. The post-analytical period is the time between result printing, verification and the physician actually receives the results. Among these three phases, other studies have shown that the pre-analytical and post-analytical phases accounts to almost 96% of the TAT [3]. These findings may vary from one health facility to the other depending on the infrastructure of the institution, degree of automation in the health facility, the experience and the skills of the staffs [10,11].

Current, data is limited on the TAT for tuberculosis (TB) testing in Cameroon. This study aimed at evaluating the intra-TAT in the diagnosis of TB in the tuberculosis reference laboratory Douala (TBRL-D’la). The outcomes of this study will be useful to improve patient satisfaction by highlighting possible causes of delay in laboratory results delivery.

Method

We conducted this cross-sectional descriptive study in the TBRL-D’la-Cameroon on all suspected TB specimens that met the TBRL-D’la sample acceptance criteria. At the reception, all samples were given a unique laboratory identification number. This identification number served as the sample’s identity throughout the testing process. Patient identification was therefore unknown by the research team throughout the intervention period. We collected data to evaluate turnaround time on a daily basis as the sample moved through each stage of analysis. At each stage, the time the testing activity began and when it ended was documented. Only samples received by 8:00 am to 2:00 pm from the 1st March to 30th April 2022 for TB diagnosis by GeneXpert MTB/RIF Ultra were considered. The laboratory activities were divided into three phases (pre-analytic, analytic, and post-analytic). The pre-analytic phase was limited to specimen reception and sorting; the analytic phase was limited to specimen testing; and the post-analytic phase included result reporting, biological validation, entering patient information into the electronic database, and printing of results.

Brainstorming among the TBRL-D’la team (with academic certificates of Ph.D, Masters, and First degree) was the tool used to identify the root causes for TAT delay. The quality manager of the TBRL-D’la acted as the facilitator. The 5-Whys problem investigation method was used to drill down to the root causes. The facilitator distributed stickers to all members of the team and asked the first why question: “What are the factors responsible for a TAT of more than 24 hours in our laboratory?” Everyone on the team wrote down an idea on the sticker. Each member of the team was given a minute to share their idea. Each idea was debated. The facilitator proceeded by asking “why” four additional times, restructuring each “why” question in response to the answer the team had just provide to the preceding question. The root cause of the delay was identified when asking “why” resulted to no additional useful responses, and the team couldn’t proceed. The team them acted on this point in attempt to resolve the identified root cause.

The identified root causes were represented on a fish-born diagram. The time interval spent by each specimen at each testing phase was measured in hours. The acceptable time for the pre-analytic phase was 3 hours, for the analytic, it was 11 hours, and for the post-analytic phase, it was 10 hours. The overall TAT was set at 24 hours. TAT was expressed as proportions. This was a noninvasive study. We didn’t have direct contact with the patients, their biological information or nor specimens. This was a noninvasive study. We didn’t have direct contact with the patients, their biological information or their specimens. We simply observe the time the Tuberculosis Reference laboratory staffs used in treating patient specimens so we didn’t obtain participants’ consent. We also did not judge it mandatory to obtain an ethical clearance from an Institutional Review Board (IRB) for this same purpose. We however obtained administrative clearance from the Ministry of Public Health with decision number No 2346/L/MINSANTE/SG/CCOUSP to carry out this study.

The data obtained from this study was entered, analyzed, and expressed as frequencies and percentages in Microsoft Excel 2016.

Results

Overall, 526 clients’ specimens were received for TB testing by GeneXpert in the months of March and April. The median TAT of samples in this study was 45 (1–120) hours. A total of 116 and 100 of our clients in March and April, for a total of 216 (41.1%), waited for more than 24 hours before their results were ready. The pre-analytic, analytic, and post-analytic phases of TB testing accounted for 64(29.6%), 128(59.3%) and 24(11.1%) TAT failure respectively. Overall, 19 root causes of TAT failure were identified. Most, nine (47.4%) of these causes were completely out of the laboratory personnel’s control, six (3.6%) were partially under their control, and four (21.1%) were completely under their control as illustrated in Fig 1.

Fig 1. Root causes for turnaround time failure in the tuberculosis reference laboratory Douala in March-April, 2022.

Fig 1

Equipment and material-related causes of TAT failure accounted for 150 (69.4%) of all causes of TAT failure. The most predominant cause of TAT failure was equipment-related (39.8%). All TAT failures attributed to the analytic phase were either associated with defective modules 80 (93.0%) of the GeneXpert equipment or these modules not being calibrated 6 (7%). Material-related causes 64 (29.6%) were the second leading cause of failing TAT. Material-related causes were attributed to poorly filled or incomplete request forms 50 (78.1%) and poor sample quality 17(21.9%). The least associated causes of TAT failure were attributed to administrative reasons six (2.8%), as illustrated in Table 1.

Table 1. Frequency distribution of causes of turnaround time failure in the tuberculosis reference laboratory in March to April 2022.

Causes of turnaround time failure Frequency Percentage
Administration 6 2.8
Environment 12 5.6
Method 20 9.3
Staff 28 13.0
Material 64 29.6
Equipment 86 39.8
Total 216 100

Discussion

In today’s modern world, where laboratory diagnosis is shifting toward point-of-care testing, the laboratory needs to deliver prompt and accurate test results to guarantee high-quality diagnostic services. TAT for laboratory reports is now a yardstick indicator of the quality of services it renders, and many medical doctor use it to evaluate the level of a laboratory’s efficiency and effectiveness [12]. The rate at which laboratory results are issued out to both the patients and the clinicians impacts both the patient outcome and the overall performance of that laboratory. We analyzed client samples received in the laboratory during the study period to generate relevant information about the TAT, a marker for their satisfaction.

In this study, 41.1% of the results of samples received in the TBRL-Douala for TB diagnosis by GeneXpert MTB/RIF Ultra were ready after the expected 24-hour waiting period. Prolonged result delivery time may delay clinical diagnosis and impact the patient’s management. This has been proven to prolonged the time patient stay in the hospital and consequently increased their financial costs [8]. The consequences of prolonged TAT have been found to be more severe with respiratory tract infectious diseases and other emergency service setting. The pre-analytic, analytic, and post-analytic phases of TB testing accounted for 29.6%, 59.3%, and 11.1% of TAT failures, respectively. These findings were similar to those obtained in New Delhi, India [13] where the pre-analytic, analytic, and post-analytics phases to complete different steps of sample processing in an auto analyzer were 30.6%, 42.6%, and 26.9%, respectively. Other studies [1416], however, found that 50–75% of the laboratory TAT failures were attributed to the pre-analytic phase because this phase is not in the direct control of laboratory personnel and also involves multiple steps and laboratory personnel. In our study, 90.7% of the delay during the analytic phase was attributed to equipment-related delays, as the laboratory was functioning on five out of 12 GeneXpert modules lodged in three instruments. Other studies have demonstrated that the equipment breakage are the most recurrent cause of laboratory result delays [12], reagent stock out has been the second on the list [17]. Other causes of a TAT failures have been attributed to the inability to modify work schedules to organize available manpower and an insufficient manpower at work [17]. Moreover, the overlap of activities caused by supportive supervision, intensive training and mentorship, of students on internships kept laboratory personnel very busy and could have delayed our TAT. Administrative tolerance was also a major cause for TAT failure in this study, given that in 2020, the maintenance of all (approximately 75) the GeneXpert instruments in the entire country was given to a subcontracting company that happens to have a limited number of trained personnel. These few people have to travel over the national territory to maintain all the GeneXpert instruments, even for minor problems. To make things worse, this company doesn’t have a single buffer stock of spare parts or replacement modules in the country. Each time a fault was signaled, a long time was wasted waiting for the local company to come onsite and certify the fault. An even greater amount of time was spent waiting for the spare part to travel from the manufacturing country.

Limitations

This study was limited to the evaluation of intra-laboratory turnaround time. We therefore recommend that a similar study be extended to cover both the intra- and extra-laboratory turnaround times to better understand the causes of prolonged patient waiting times to acquire laboratory service for TB diagnosis in the littoral region of Cameroon.

Conclusion

Monitoring TAT for TB diagnosis is crucial as a marker of patient satisfaction and identification of possible causes for delay in laboratory results delivery. This study revealed that GeneXpert maintenance, especially delays in module replacement, was responsible for most of the analytic testing phase TAT failures. We encourage open policies with competition for all laboratory equipment and the availability of a buffer stock of essential spares parts and replacement modules in-Country.

Supporting information

S1 File. TAT data for plos one.

(XLSX)

pone.0323917.s001.xlsx (99.4KB, xlsx)

Acknowledgments

The authors thank all the Tuberculosis Reference Laboratory Douala staffs who provided us with very useful information which enabled us identify root causes for TAT failure.

Data Availability

The datasets used and/or analyzed during the current study are available with the manuscript, since it is uploaded as supplementary information.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.I. O. Medicine. To err is human: Building a safer health system. Shap. Futur. Heal., no. November, pp. 1–8, 1999. Available from: doi: 10.17226/9728 [DOI] [Google Scholar]
  • 2.Stotler BA, Kratz A. Determination of turnaround time in the clinical laboratory: “accessioning-to-result” time does not always accurately reflect laboratory performance. Am J Clin Pathol. 2012;138(5):724–9. doi: 10.1309/AJCPYHBT9OQRM8DX [DOI] [PubMed] [Google Scholar]
  • 3.Bhatt RD, Shrestha C, Risal P. Factors affecting turnaround time in the clinical laboratory of the Kathmandu University Hospital, Nepal. Electron J Int Fed Clin Chem Lab Med. 2019;30(1):14–24. [PMC free article] [PubMed] [Google Scholar]
  • 4.Alain CB, Rostin MMM, Joël KNN, Hypolite MM, Donatien KN-N, Koffi TA, et al. Evaluation of Clinical Laboratory Tests’ Turnaround Time in a Tertiary Hospital in Democratic Republic of the Congo. JBM. 2021;09(07):96–111. doi: 10.4236/jbm.2021.97011 [DOI] [Google Scholar]
  • 5.Michael M, Schaffer SD, Egan PL, Little BB, Pritchard PS. Improving wait times and patient satisfaction in primary care. J Healthc Qual. 2013;35(2):50–9; quiz 59–60. doi: 10.1111/jhq.12004 [DOI] [PubMed] [Google Scholar]
  • 6.Holland LL, Smith LL, Blick KE. Reducing Laboratory Turnaround Time Outliers Can Reduce Emergency Department Patient Length of Stay. Am J Clin Pathol. 2005;124(5):672–4. doi: 10.1309/e9qpvq6g2fbvmj3b [DOI] [PubMed] [Google Scholar]
  • 7.Angeletti S, De Cesaris M, Hart JG, Urbano M, Vitali MA, Fragliasso F, et al. Laboratory Automation and Intra-Laboratory Turnaround Time: Experience at the University Hospital Campus Bio-Medico of Rome. J Lab Autom. 2015;20(6):652–8. doi: 10.1177/2211068214566458 [DOI] [PubMed] [Google Scholar]
  • 8.Mutema L, Chapanduka Z, Musaigwa F, Mashigo N. In-depth investigation of turn-around time of full blood count tests requested from a clinical haematology outpatient department in Cape Town, South Africa. Afr J Lab Med. 2021;10(1):1318. doi: 10.4102/ajlm.v10i1.1318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization. SLMTA trainer’s guide - module 8 - lab testing. World Heal. Organ. 2015. Available from: https://slmta.org/resource/training/teaching-guide/11-module8-laboratory-testing.pdf [Google Scholar]
  • 10.Hawkins R. Pre and Post Analytical Factors Affecting Laboratory Results. SFP. 2017;43(4):6–10. doi: 10.33591/sfp.43.4.u1 [DOI] [Google Scholar]
  • 11.De la Salle B. Pre- and postanalytical errors in haematology. Int J Lab Hematol. 2019;41 Suppl 1:170–6. doi: 10.1111/ijlh.13007 [DOI] [PubMed] [Google Scholar]
  • 12.Dawande PP, Wankhade RS, Akhtar FI, Noman O. Turnaround time: an efficacy measure for medical laboratories. Cureus. 2022;14(9). doi: 10.7759/cureus.28824 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bhutani N, Bhutani N. An Analysis of Preanalytical Errors and Turnaround Time in Emergency Biochemistry Laboratory in a Tertiary Care Hospital in New Delhi. jemds. 2020;9(13):1065–8. doi: 10.14260/jemds/2020/229 [DOI] [Google Scholar]
  • 14.Cakirca G. The Evaluation of Error Types and Turnaround Time of Preanalytical Phase in Biochemistry and Hematology Laboratories. Iran J Pathol. 2018;13(2):173–8. [PMC free article] [PubMed] [Google Scholar]
  • 15.Chandrashekhar GS. Total turnaround time of clinical laboratory-an assessment tool for laboratory performance. IOSR J Dent Med Sci. 2018;17(9):6–09. doi: 10.9790/0853-1709030609 [DOI] [Google Scholar]
  • 16.Sangam S, Naveed A, Athar M, Prathyusha P, Moulika S, Lakshmi S. Laboratory Turnaround Time. Int J Heal Sci Res. 2015;5(1) 156–64. https://www.ijhsr.org/IJHSR_Vol.3_Issue.5_May2013/13.pdf [Google Scholar]
  • 17.Hawkins RC. Laboratory turnaround time. Clin Biochem Rev. 2014;8(4):179–94. [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Talkmore Maruta

16 Jan 2025

PONE-D-24-50358Evaluating Turnaround Time to Improve Clients' Satisfaction in the Tuberculosis Reference Laboratory in DoualaPLOS ONE

Dear Dr. Mbuh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Talkmore Maruta, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. In the online submission form, you indicated that the datasets used and/or analyzed during the current study are available from the corresponding author teyimpride@yahoo.com upon reasonable request. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

4. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. 

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jun 13;20(6):e0323917. doi: 10.1371/journal.pone.0323917.r003

Author response to Decision Letter 1


12 Feb 2025

A rebuttal letter for the manuscript titled: Evaluating Turnaround Time to Improve Clients' Satisfaction in the Tuberculosis Reference Laboratory in Douala submitted to PLOS ONE reference PONE-D-24-50358

SN Reviewers’ preoccupation Response provided

1 Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Thanks, the manuscript has been reformatted to meets PLOS ONE's style requirements, including those for file naming.

2 Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

This was a noninvasive study. We didn’t have direct contact with the patients, their biological information or their specimens. We simply observed the time laboratory staffs used in treating patient specimens so we didn't obtain participants' consent.

This is clearly stated in the manuscript in the method (lines 119-121) and the declaration (lines 203-205)

3 In the online submission form, you indicated that the datasets used and/or analyzed during the current study are available from the corresponding author teyimpride@yahoo.com upon reasonable request.

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

the datasets used and/or analyzed during the current study are available with the manuscript, since it was uploaded as supplementary information. This in found in the manuscript in lines 239-240

4 Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

The dataset shared doesn’t contain any personal information that may compromise or identify the study participant

5 Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

A caption for the datasets used and/or analyzed during the current study was included.

6 Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Thanks, this has been done

Attachment

Submitted filename: AREBUT~2.DOC

pone.0323917.s003.DOC (13.5KB, DOC)

Decision Letter 1

Enoch Aninagyei

17 Apr 2025

Evaluating turnaround time to Improve clients' satisfaction in the tuberculosis reference laboratory in Douala

PONE-D-24-50358R1

Dear Dr. Mbuh,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Enoch Aninagyei, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors submitted an important study topic and rationally put causes of delay in TAT. Although this is a qualitative study needs minimal analysis but expressed well caused behind prolonged. Authors responded well to reviewers comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  LAYTH AL-SALIHI

**********

Acceptance letter

Enoch Aninagyei

PONE-D-24-50358R1

PLOS ONE

Dear Dr. Mbuh,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Enoch Aninagyei

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. TAT data for plos one.

    (XLSX)

    pone.0323917.s001.xlsx (99.4KB, xlsx)
    Attachment

    Submitted filename: AREBUT~2.DOC

    pone.0323917.s003.DOC (13.5KB, DOC)

    Data Availability Statement

    The datasets used and/or analyzed during the current study are available with the manuscript, since it is uploaded as supplementary information.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES